287 related articles for article (PubMed ID: 11109640)
21. Economic evaluation of standing order programs for pneumococcal vaccination of hospitalized elderly patients.
Middleton DB; Lin CJ; Smith KJ; Zimmerman RK; Nowalk MP; Roberts MS; Fox DE
Infect Control Hosp Epidemiol; 2008 May; 29(5):385-94. PubMed ID: 18521990
[TBL] [Abstract][Full Text] [Related]
22. Vaccination of risk groups in England using the 13 valent pneumococcal conjugate vaccine: economic analysis.
Rozenbaum MH; van Hoek AJ; Fleming D; Trotter CL; Miller E; Edmunds WJ
BMJ; 2012 Oct; 345():e6879. PubMed ID: 23103369
[TBL] [Abstract][Full Text] [Related]
23. Cost-Effectiveness Analysis of Universal Vaccination of Adults Aged 60 Years with 23-Valent Pneumococcal Polysaccharide Vaccine versus Current Practice in Brazil.
de Soárez PC; Sartori AM; Freitas AC; Nishikawa ÁM; Novaes HM
PLoS One; 2015; 10(6):e0130217. PubMed ID: 26114297
[TBL] [Abstract][Full Text] [Related]
24. Epidemiologic impact and cost-effectiveness of universal infant vaccination with a 7-valent conjugated pneumococcal vaccine in the Netherlands.
Bos JM; Rümke H; Welte R; Postma MJ
Clin Ther; 2003 Oct; 25(10):2614-30. PubMed ID: 14667962
[TBL] [Abstract][Full Text] [Related]
25. [Cost-effectiveness analysis of pneumococcal vaccination in Spain].
Morano R; Pérez F; Brosa M; Pérez Escolano I
Gac Sanit; 2011; 25(4):267-73. PubMed ID: 21640443
[TBL] [Abstract][Full Text] [Related]
26. Economic evaluation of pneumococcal vaccines for adults aged over 50 years in Belgium.
Willem L; Blommaert A; Hanquet G; Thiry N; Bilcke J; Theeten H; Verhaegen J; Goossens H; Beutels P
Hum Vaccin Immunother; 2018 May; 14(5):1218-1229. PubMed ID: 29420161
[TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales.
Melegaro A; Edmunds WJ
Vaccine; 2004 Oct; 22(31-32):4203-14. PubMed ID: 15474710
[TBL] [Abstract][Full Text] [Related]
28. Cost-effectiveness of pneumococcal vaccination strategies for the elderly in Korea.
Heo JY; Seo YB; Choi WS; Lee J; Noh JY; Jeong HW; Kim WJ; Kim MJ; Lee HY; Song JY
PLoS One; 2017; 12(5):e0177342. PubMed ID: 28498857
[TBL] [Abstract][Full Text] [Related]
29. Incremental cost-effectiveness evaluation of vaccinating girls against cervical cancer pre- and post-sexual debut in Belgium.
Demarteau N; Van Kriekinge G; Simon P
Vaccine; 2013 Aug; 31(37):3962-71. PubMed ID: 23777952
[TBL] [Abstract][Full Text] [Related]
30. Cost-effectiveness and Health Benefits of Pediatric 23-valent Pneumococcal Polysaccharide Vaccine, 7-valent Pneumococcal Conjugate Vaccine and Forecasting 13-valent Pneumococcal Conjugate Vaccine in China.
Mo X; Gai Tobe R; Liu X; Mori R
Pediatr Infect Dis J; 2016 Nov; 35(11):e353-e361. PubMed ID: 27753771
[TBL] [Abstract][Full Text] [Related]
31. Cost-benefit and cost-effectiveness of the incorporation of the pneumococcal 7-valent conjugated vaccine in the routine vaccination schedule of Catalonia (Spain).
Navas E; Salleras L; Gisbert R; Domínguez A; Timoner E; Ibáñez D; Prat A
Vaccine; 2005 Mar; 23(17-18):2342-8. PubMed ID: 15755625
[TBL] [Abstract][Full Text] [Related]
32. Cost of pneumococcal infections and cost-effectiveness analysis of pneumococcal vaccination at risk adults and elderly in Turkey.
Akin L; Kaya M; Altinel S; Durand L
Hum Vaccin; 2011 Apr; 7(4):441-50. PubMed ID: 21441776
[TBL] [Abstract][Full Text] [Related]
33. The cost-effectiveness of pneumococcal conjugate vaccination in Australia.
Butler JR; McIntyre P; MacIntyre CR; Gilmour R; Howarth AL; Sander B
Vaccine; 2004 Mar; 22(9-10):1138-49. PubMed ID: 15003641
[TBL] [Abstract][Full Text] [Related]
34. Cost-effectiveness of adult vaccination strategies using pneumococcal conjugate vaccine compared with pneumococcal polysaccharide vaccine.
Smith KJ; Wateska AR; Nowalk MP; Raymund M; Nuorti JP; Zimmerman RK
JAMA; 2012 Feb; 307(8):804-12. PubMed ID: 22357831
[TBL] [Abstract][Full Text] [Related]
35. Cost-effectiveness analysis of pneumococcal vaccination for elderly individuals in The Netherlands.
Postma MJ; Heijnen ML; Jager JC
Pharmacoeconomics; 2001; 19(2):215-22. PubMed ID: 11284385
[TBL] [Abstract][Full Text] [Related]
36. Retrospective economic evaluation of childhood 7-valent pneumococcal conjugate vaccination in Australia: Uncertain herd impact on pneumonia critical.
Newall AT; Reyes JF; McIntyre P; Menzies R; Beutels P; Wood JG
Vaccine; 2016 Jan; 34(3):320-7. PubMed ID: 26657187
[TBL] [Abstract][Full Text] [Related]
37. Comparing health outcomes and costs of general vaccination with pneumococcal conjugate vaccines in Sweden: a Markov model.
By A; Sobocki P; Forsgren A; Silfverdal SA
Clin Ther; 2012 Jan; 34(1):177-89. PubMed ID: 22284997
[TBL] [Abstract][Full Text] [Related]
38. Pharmacoeconomics of elderly vaccination against invasive pneumococcal infections: cost-effectiveness analyses and implications for The Netherlands.
Postma MJ; Heijnen ML; Beutels P; Jager JC
Expert Rev Vaccines; 2003 Aug; 2(4):477-82. PubMed ID: 14711333
[TBL] [Abstract][Full Text] [Related]
39. Cost-effectiveness of vaccinating the elderly and at-risk adults with the 23-valent pneumococcal polysaccharide vaccine or 13-valent pneumococcal conjugate vaccine in the UK.
Jiang Y; Gauthier A; Keeping S; Carroll S
Expert Rev Pharmacoecon Outcomes Res; 2014 Dec; 14(6):913-27. PubMed ID: 25189087
[TBL] [Abstract][Full Text] [Related]
40. Cost-effectiveness of using 2 vs 3 primary doses of 13-valent pneumococcal conjugate vaccine.
Stoecker C; Hampton LM; Link-Gelles R; Messonnier ML; Zhou F; Moore MR
Pediatrics; 2013 Aug; 132(2):e324-32. PubMed ID: 23821695
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
